Treatment of allergies and asthma is changing all the time, and with so many people around the United States suffering from the diseases, scientists are constantly trying to come up with new ways to treat patient symptoms.
In a recent release, researchers from Washington University announced that they believe they have come up with a viable treatment option for infants who suffer from wheezing and are hospitalized for respiratory syncytial virus (RSV).
According to Avraham Beigelman, MD, and his research team at Washington University, the antibiotic azithromycin may work to reduce the wheezing in patients who suffer from RCV.
In addition to helping babies breathe easier in real time, administration of the drug and reduced levels of wheezing may also actually lessen the risk of developing asthma later in life.
"Almost all children will get an RSV infection during the first two years of life," Beigelman told Health Canal. "But only a small fraction of these children are admitted to a hospital and have the very highest risk of developing recurrent wheezing and asthma. Researchers at Washington University have found that up to 80 percent of infants admitted to a hospital for bronchiolitis will have three or more wheezing episodes during the six years following the RSV hospitalization."
The team conducted a study which examined the impact that administration of the drug had on these babies. It showed a marked decrease in the respiratory symptoms of children who were given the antibiotic, which could mean a potential course of treatment going forward.
For your children, or yourself, it is key that you are aware of the best asthma and allergy control techniques that exist. To learn more about how Allergy Be Gone can help, contact us today!
